Citigroup
SONN

Citigroup’s Sonnet BioTherapeutics SONN Stock Holding History

Citigroup’s Portfolio SONN Stock Details SONN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-134
Closed -$614 – 6441
2025
Q3 		$614 Buy
+134
New +$594 ﹤0.01% 5688
2025
Q1 		– Sell
-2
Closed -$3 – 5935
2024
Q4 		$3 Buy
+2
New +$7 ﹤0.01% 5798
2024
Q2 		– Sell
-5
Closed -$71 – 5768
2024
Q1 		$71 Buy
+5
New +$67 ﹤0.01% 5507
2023
Q4 		– Hold
0
– -$9 – 5855
2023
Q3 		– Hold
0
– – – 5618
2021
Q3 		– Hold
0
– -$2K – 6264
2021
Q2 		– Hold
0
– – – 5990
2014
Q1 		– Hold
0
– -$4K – 7190
2013
Q4 		– Hold
0
– – – 6671

Other funds holding SONN

FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

Citigroup's SONN Position: Q4 2025 in Review

Citigroup sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 134 shares — an estimated $614 sold.

Citigroup first reported a position in SONN in Q1 2024 and held it in 3 quarters. The position peaked at $614 in Q3 2025. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.

  • Citigroup reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 134 Sonnet BioTherapeutics shares in Q4 2025, an estimated $614.
  • Citigroup first reported a position in Sonnet BioTherapeutics in Q1 2024 and held it in 3 quarters.
  • Citigroup's Sonnet BioTherapeutics position peaked at $614 in Q3 2025.
  • 1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.